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Acute myocarditis is an uncommon complication of
influenza with a high mortality [1]. Early therapy
with neuraminidase inhibitors (NI) is recommended
in patients hospitalized for influenza, notably those
with myocarditis. Oral oseltamivir is generally used
as the first line NI therapy, whereas parenteral
zanamivir and peramivir represent alternatives in
selected patients who might not respond to oselta-
mivir, as may occur in conditions of gut failure and
defective enteral drug absorption [2, 3]. We present
two patients with influenza myocarditis complicated
by enteral drug malabsorption, who received early
intravenous zanamivir therapy with excellent clin-
ical outcomes.
Patient 1 is a 49-year old woman, admitted with
hypotension (71/47 mmHg), high hsTroponin T (up
to 1570 ng/l), severe cardiac dysfunction (left
ventricular ejection fraction (LVEF) of 20%), and
positive naso-pharyngeal swabs for influenza B.
Patient 2 is a 30-year old woman admitted with
hypotension (82/54 mmHg), severe cardiac dys-
function (LVEF of 15%), elevated hsTroponin T
(up to 3643 ng/l), and positive swabs for influenza
A. Both patients received oral oseltamivir (300 mg
daily) and intravenous catecholamines (Fig. 1). In
both, extracorporeal life support (ECLS) was
started at day 2 for refractory cardiogenic shock.
Given clinical deterioration, enteral drug absorp-
tion was assessed at day 4 for patient 1 and day 2
for patient 2 by a paracetamol absorption test [4],
which measures sequential plasma paracetamol
levels after enteral loading (via nasogastric tube)
with 1000 mg paracetamol. A marked impairment
of enteral drug absorption was identified in both
patients, leading to a switch from oral oseltamivir
to parenteral zanamivir (patient 1, 600 mg daily,
adapted to renal function, from days 5 to 15; pa-
tient 2, 1200 mg daily, from days 2 to 12). In the
following days, catecholamines were steadily re-
duced, LVEF progressively improved, and ECLS
was weaned (patient 1, day 12; patient 2, day 10).
At ICU discharge, LVEF was 55% and 45%,
respectively.
In these two patients with influenza myocarditis
and refractory cardiogenic shock, the rapid identifi-
cation of poor drug absorption using a simple para-
cetamol absorption test allowed the early
introduction of parenteral zanamivir instead of oral
oseltamivir, with excellent clinical outcomes. Since
drug malabsorption is frequent in critically ill
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patients with circulatory shock [5], we propose that
a paracetamol pharmacokinetic study be performed
early in patients with influenza myocarditis and
cardiogenic shock to avoid any delay in the admin-
istration of parenteral therapy if enteral drug mal-
absorption is demonstrated.
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Fig. 1 Time-course of LVEF, catecholamines, and ECLS in two patients with fulminant influenza myocarditis. LVEF rapidly increased, allowing weaning
of norepinephrine (NE), epinephrine (Epi), and extracorporeal life support (ECLS), after switching from oral oseltamivir to intravenous (IV) zanamivir,
following a paracetamol absorption test (P.A.T.) showing enteral drug malabsorption (insert). The reference values for the test were obtained from [4]
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